Editor-in-Chief
Zhe-Sheng Chen
Professor Department of Pharmaceutical Sciences College of Pharmacy and Allied Health Professions St. John’s University · United States
Editorial leadership for Journal of New Developments in Chemistry ISSN 2377-2549
Research interests
- Our Primary Goal Is To Develop More Effective Chemotherapeutic Agents For Cancer Patients.&Nbsp;&Nbsp; Multidrug Resistance (Mdr) Represents A Major Obstacle To The Treatment Of Cancer
- And Understanding The Resistance Mechanisms
- Knowing How To Reverse The Resistance Hold The Promise Of Providing Insights That May Lead To Improvements In The Use Of Currently Available Anticancer Drugs.&Nbsp;&Nbsp; Our Laboratory Is Interested In The Molecular
- Cellular Pharmacology Of Anticancer Drugs
- Such As Drug Resistance Mechanisms
- Reversal Of Resistance Study
- New Drug Development.&Nbsp;&Nbsp; A Promise Of Our Research Program Is That Progress In The Chemotherapy Of Cancer Will Depend On Rational Combination Of Agents That Reduce The Function Of Plasma Membrane Transporters Such As P-Gp
- Abcg2
- Mrps
- And To Enhance The Actions Of Cytotoxic Drugs.&Nbsp;&Nbsp; In Collaboration With Many Researchers In Usa
- China
- Japan
- Canada
- Australia
- Egypt
- Studies In Our Laboratory Focus On Screening
- Identifying New Inhibitors Of Abc Transporters By In Vitro Membrane Vesicles Transport Assay System
- Cell Based Assay Systems.&Nbsp;&Nbsp; Another Research Direction Is To Study The Role Of Abc Transporters Family On The Detoxification Of Chemicals (Including Carcinogens
- Mutagens) Using Knock Out Mouse Models.&Nbsp;&Nbsp; In Addition
- I Have A Strong Scientific Writing
- Communication Skills (Grants
- Publications) As Well As Am Active In Public Service With Global
- Local Impact
Biography
- Dr. Zhe-Sheng (Jason) Chen, M.D., PhD, is currently a Professor at College of Pharmacy and Health Sciences, St. John’s University.
- He joined St. John’s University in 2004 as an assistant professor.
- He established several research projects to study ABC transporters and multidrug resistance (MDR) as well as reversal of MDR in both in vitro and in vivo tumor models.
- During past years, his laboratory has been well funded by NIH and companies.
- He carried out his postdoctoral training at Fox Chase Cancer Center (Philadelphia, USA, 2000-2004) and Kagoshima University Faculty of Medicine (Japan, 1998-2000).
- He received his Ph.D. degree from Kagoshima University Faculty of Medicine (Japan, 1994-1998), Master degree from Sun Yat-Sen University School of Public Health (China, 1985-1988) and M.D. from Guangdong Medical and Pharmaceutical College (China, 1980-1985).
- Dr. Chen is an editor-in-chief of Journal of Cancer Research Updates, and New Developments on Chemistry, an editor of African Journal of Pharmacy and Pharmacology, Regional Editor of Recent Patents on Anticancer Drugs Discovery, a guest editor of Current Pharmaceutical Biotechnology, an editorial board member of more than 20 journals and a reviewer of more than 170 peer reviewed journals.
- He is also an Ad hoc reviewer of some grants such as NIH, NCI Special Emphasis Review Panel, OmniBus SEP-10, State Grant Reviewer for Louisiana, and grants for New Zealand, Poland, China, Hungary, and Netherlands etc.
- As a consultant to pharmaceutical, biotechnology and health industry organizations,
- Dr. Chen commands invitations for presentations, keynote addresses, and conference chairman.
- He published more than 150 publications in peer reviewed journals and 5 book chapters.
Considering JNDC for your work?
This journal is guided by Zhe-Sheng Chen (Professor Department of Pharmaceutical Sciences College of Pharmacy and Allied Health Professions St. John’s University) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.